About 67 results for "dusa pharmaceuticals"

Export-driven growth makes up for slowing domestic sales

India pharmaceuticals market: 18% growth between 2012-2016

India pharma rode on the wave of bunched up patent expiries in the US with many Para IV launches in 2012. In addition, it also benefited from the continuing high teen growth of Indian pharma market. With patent expiries in the US dwindling from $30b ... TransWorldNews, 3 days ago

Pharmaceuticals Newsletter - 08 April to 12 April, 2013 - India Infoline, 1 month ago

Export-driven growth makes up for slowing domestic sales - Sify, 1 month ago

Brokers' call: Sun Pharma remains a buy

Morgan Stanley has maintained a 'Buy' rating on Sun Pharmaceuticals with an 'Overweight' rating with a target price of Rs 1,159. Sun is transforming its top-quality generic business into a specialty company. "We believe it can unlock meaningful ...

Economic Times, 1 week ago Morgan Stanley sees more upside in Sun Pharma Economic Times, 1 week ago Buy Sun Pharma, says Espirito Santo Securities Smart Investor, 1 month ago

Moneycontrol.com

Sun Pharma touches record high, taking its m-cap above combined mkt value of DRL, Lupin & Cipla

MUMBAI: The stock of Sun Pharmaceuticals hit a record high on Tuesday, catapulting its market capitalisation above that of Dr Reddy's Laboratories, Cipla and Lupin put together. An impressive revenue and profit growth, benefits from overseas ...

Economic Times, 2 weeks ago Sun Pharma's bigger than three rivals put together Economic Times, 2 weeks ago Sun Pharmaceuticals' stock hit a record high Economic Times, 2 weeks ago Sun Pharma hits record high, mkt cap exceeds Rs 1 lakh cr | Quote Economic Times, 2 weeks ago

Rediff.com

The Indian Pharmaceutical Industry 2013: Coming of Age in a Global Market

NEW YORK, Jan. 30, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: ...

AndhraNews.net, 1 month ago Sun eyes US skincare market Rediff.com, 1 month ago Drug Delivery: Surveying the Global Competitive Landscape Research and Markets, 3 weeks ago Dermatological Drugs: World Market Prospects 2013-2023 ADVFN India, 3 weeks ago

More from: Los Angeles Business, Sys-Con Belgium...and 5 other sources

[x]

InsiderMonkey.com

SciClone Pharmaceuticals, Inc. (SCLN): Insiders Aren't Crazy About It

Is SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ) an attractive investment today? The best stock pickers are becoming more confident. The number of long hedge fund bets moved up by 2 lately. According to most traders, hedge funds are perceived ...

InsiderMonkey.com, 3 weeks ago

SMaRT Therapeutics Announces Appointment of Dr. John H. Abeles to the Advisory Board

Dr. Abeles has had a long and distinguished career in the biotechnology and pharmaceutical industries. He practiced medicine in London "I'm excited to join SMaRT's Advisory Board at this dynamic and strategically determinative time," commented Dr.

Street Insider, 3 weeks ago Smart Therapeutics (BSX) Announces Appointment of Dr. John H. Abeles to the Advisory Board FierceBiotech, 3 weeks ago SMaRT Therapeutics Appoints Dr. John H. Abeles to the Advisory Board Citybizlist, 3 weeks ago

More from: Yahoo! Finance, TickerTech.com...and 7 other sources

[x]

Sun Pharma: Strong base, acquisitions to help maintain growth momentum

Related to : Sun Pharmaceuticals Industries Ltd Sun Pharmaceuticals Industries Ltd BSE 03 Apr 13 | 03:48 PM 864.60 13.1 (1.54%) NSE 03 Apr 13 | 03:31 PM 864.30 13 (1.53%) Sun Pharma has been one of the outperformers in FY13 breaking into the top ...

Smart Investor, 1 month ago Strong base, new acquisitions to help maintain growth momentum Smart Investor, 1 month ago

My Thoughts On Taro

This is the third article I have written in the last two years on TARO Pharmaceutical Industries (TARO). TARO is a generic drug manufacturer based out of Israel with its functional headquarters in the United States. It has been the subject of two ...

Seeking Alpha, 1 month ago

Obagi's Acquisition By Valeant Defines A Value For DS Healthcare

In an effort to increase its presence in skin care, Valeant Pharmaceuticals International (VRX) just bought DS Healthcare Group's (DSKX) closest competitor in aesthetic treatments, Obagi Medical Products (OMPI). The deal was consummated at a solid ...

Seeking Alpha, 1 month ago

WCUI's Psoria-Shield® Announces Sales Roll-Out of Psoria-Light® to Key Markets

/PRNewswire/ -- Wellness Center USA , Inc. (OTCQB: WCUI), a Schaumburg, IL alternative healthcare company, is pleased to announce that wholly-owned subsidiary Psoria-Shield has rolled out its domestic sales program for Psoria-Light and sales are ...

Barchart, 1 day ago WCUI's Psoria-Shield(R) Announces Sales Roll-Out of Psoria-Light(R) to Key Markets SpaceRef, 1 day ago

More from: , Individual.com...and 5 other sources, Individual.com...and 5 other sources

[x]

Prev | Next

About 67 results for "dusa pharmaceuticals"

Related Queries - dusa pharmaceuticals